Lynparza is commonly used to treat ovarian cancer and certain other cancers. Lynparza slows the growth of cancer cells.

Primary peritoneal cancer is a rare type of cancer. The disease develops from malignant epithelial and mesothelial cells of the peritoneum. If not detected and treated promptly, these cells will spread to the entire peritoneum, metastasize by blood and lymphatic routes.

Peritoneal cancer is a rare cancer. Peritoneal cancer is often detected at an advanced stage because the symptoms are not obvious in the early stages, making it difficult to diagnose.

Niraparib is a PARP inhibitor. It is indicated for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have responded partially or completely to chemotherapy.